Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

27.74 -0.04 (-0.14%)

Delayed Quote Updated: 2:46 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

69 Biggest Movers From Friday ↗

June 06, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...

Via Benzinga

Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher ↗

June 03, 2022

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 300 points on Friday.

Via Benzinga

Expert Ratings For Amylyx Pharmaceuticals ↗

April 01, 2022

Within the last quarter, Amylyx Pharmaceuticals (NASDAQ:AMLX) has observed the following analyst ratings:

Via Benzinga

FDA Panel Votes Down For Amylyx's ALS Drug, Further Fading Its Hope For Regulatory Success ↗

March 31, 2022

An advisory committee of the

Via Benzinga

Amylyx Pharma Stock Hinges On This FDA Action — Here's What To Know ↗

March 30, 2022

Amylyx is facing an FDA advisory committee Wednesday that will vote on its ALS drug.

Via Investor's Business Daily

Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate ↗

June 03, 2022

The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals (NASDAQ: AMLX) for its lead drug candidate AMX0035...

Via Benzinga

Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning ↗

June 03, 2022

Novavax (NVAX) stock is falling on Friday after the FDA requested a heart inflammation warning for the company's Covid-19 vaccine.

Via InvestorPlace

Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump ↗

June 03, 2022

U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday.

Via Benzinga

40 Stocks Moving In Friday's Mid-Day Session ↗

June 03, 2022

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.

Via Benzinga

Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today? ↗

June 03, 2022

Amylyx Pharmaceuticals (AMLX) stock is rising higher on Friday following an update from the U.S. Food and Drug Administration (FDA).

Via InvestorPlace

Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May ↗

June 03, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday.

Via Benzinga

Former Red-Hot IPO Amylyx Soars On New Hopes For Its ALS Drug ↗

June 03, 2022

The FDA pushed its review date for Amylyx Pharmaceuticals' controversial ALS treatment on Friday, and the biotech stock skyrocketed.

Via Investor's Business Daily

Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today ↗

June 03, 2022

Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug...

Via Benzinga

Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS

June 03, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗

May 31, 2022

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...

Via Benzinga

Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting

May 26, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022 ↗

May 25, 2022

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of...

Via Benzinga

Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization

May 16, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results

May 12, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS

May 05, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

92 Biggest Movers From Friday ↗

May 09, 2022

Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting

April 02, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest ↗

April 01, 2022

One analyst says Reata only has a 50% chance in a neurodegenerative disease.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022 ↗

April 01, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall ↗

March 31, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results

March 30, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS

March 30, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Amylyx Pharmaceuticals Stock Trading Halted Today

March 30, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.